Ipca Laboratories Limited is an Indian multinational pharmaceutical company headquartered in Mumbai, Maharashtra. The company is engaged in the manufacture and marketing of active pharmaceutical ingredients (APIs), formulations, and intermediates, with a particular focus on therapeutic areas such as cardiovascular medicine, antimalarials, pain management, rheumatology, and antibacterials. It is among the leading Indian producers of antimalarial drugs and supplies products to markets across India, Europe, Africa, the Americas, and Asia.
| Type | Public limited company |
|---|---|
| Industry | Pharmaceuticals |
| Headquarters | Mumbai, Maharashtra, India |
| Area served | India and international markets |
| Listings | Bombay Stock Exchange, National Stock Exchange of India |
| Key therapeutic areas | Antimalarials, cardiovascular, pain management, rheumatology, antibacterials |
Ipca Laboratories operates as a fully integrated pharmaceutical company, meaning it produces both finished dosage formulations and the active pharmaceutical ingredients that go into them. This vertical integration has helped the company maintain cost competitiveness, particularly in its antimalarial portfolio, where it is recognised internationally as a major supplier. The company manufactures medicines such as chloroquine, hydroxychloroquine, and artemisinin-based combination therapies, alongside a wide range of cardiovascular and rheumatology products.
The company runs multiple manufacturing facilities in India producing APIs, intermediates, and formulations in various dosage forms including tablets, capsules, injectables, ointments, and powders. Its sites have, over time, been inspected and approved by major regulatory authorities, enabling exports to regulated markets in Europe and elsewhere. Ipca also undertakes contract manufacturing for international pharmaceutical companies and supplies institutional buyers in the public health sector.
Ipca Laboratories is regarded as a significant player in the Indian pharmaceutical industry, especially in the global antimalarial supply chain. Its products feature in public health programmes addressing malaria in Africa and Asia, and it is also a substantial supplier of bulk drugs to other formulators worldwide. The company's combined API and formulation capabilities place it among India's mid-to-large pharmaceutical manufacturers by scale and export reach.